Ascelia Pharma
Logotype for Ascelia Pharma

Ascelia Pharma (ACE) investor relations material

Ascelia Pharma Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Ascelia Pharma
Q3 2026 earnings summary6 Nov, 2026

Executive summary

  • Q3 priorities: evaluate U.S. and European regulatory paths for Orviglance, continue partnering efforts, and prepare Oncoral development and outreach.

  • FDA minutes identified clinical utility as the key remaining question; prospective reanalysis of existing SPARKLE images using a new primary endpoint may address the evidence requirement.

Financial highlights

  • Q3 operating loss was SEK 10.4m versus SEK 15.3m; net loss was SEK 10.3m versus SEK 15.7m, primarily reflecting lower R&D and personnel costs.

  • Q3 R&D costs were SEK 7.8m and SG&A costs SEK 2.6m, down from SEK 8.8m and SEK 3.3m in Q2.

  • 9M operating loss was SEK 39.0m versus SEK 58.6m; net loss was SEK 38.7m versus SEK 60.4m.

  • Liquid assets were SEK 27.8m at 30 September 2026, versus SEK 72.3m a year earlier and SEK 49.9m at year-end 2025.

Outlook and guidance

  • Cash runway is expected to extend into Q2 2027; priorities include FDA feedback on a proposed SPARKLE reanalysis and European regulatory feedback on the current data package.

  • U.S. regulatory planning using existing SPARKLE data depends on FDA acceptance; further clinical studies may be required.

  • Orviglance partnering efforts continue; Oncoral is positioned to advance toward Phase 2, with development and partnering preparations ongoing.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Ascelia Pharma earnings date

Logotype for Ascelia Pharma
Q4 202611 Feb, 2027
Ascelia Pharma
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Ascelia Pharma earnings date

Logotype for Ascelia Pharma
Q4 202611 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Ascelia Pharma is an oncology-focused orphan drug development company with a portfolio of over 17 development stage drug candidates in a variety of cancer indications. Ascelia Pharma is headquartered in Malmö, Sweden.